Sivik Global Healthcare’s CRISPR Therapeutics CRSP Stock Holding History

Sivik Global Healthcare’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-25,000	Closed	-$1.9M	–	53
2021 Q4	$1.9M	Buy	+25,000	New	+$2.18M	0.81%	43
2020 Q3	–	Sell	-30,000	Closed	-$2.21M	–	49
2020 Q2	$2.21M	Buy	+30,000	New	+$1.75M	0.73%	46
2020 Q1	–	Sell	-25,000	Closed	-$1.52M	–	46
2019 Q4	$1.52M	Buy	+25,000	New	+$1.36M	0.57%	47
2018 Q3	–	Sell	-35,000	Closed	-$2.06M	–	64
2018 Q2	$2.06M	Buy	+35,000	New	+$1.99M	0.79%	49

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sivik Global Healthcare's CRSP Position: Q1 2022 in Review

Sivik Global Healthcare sold out of CRISPR Therapeutics (CRSP) in Q1 2022, closing a stake of 25,000 shares — an estimated $1.9M sold.

Sivik Global Healthcare first reported a position in CRSP in Q2 2018 and held it in 4 quarters. The position peaked at $2.21M in Q2 2020. 447 funds tracked by Wall St. Rank hold CRSP as of Q1 2022.

Sivik Global Healthcare reported no remaining CRISPR Therapeutics position as of Q1 2022 after selling out during the quarter.
Sivik Global Healthcare sold 25,000 CRISPR Therapeutics shares in Q1 2022, an estimated $1.9M.
Sivik Global Healthcare first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 4 quarters.
Sivik Global Healthcare's CRISPR Therapeutics position peaked at $2.21M in Q2 2020.
447 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2022.

Based on Sivik Global Healthcare's 13F filing for Q1 2022, filed 9 May 2022.